Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) Products under Development by Stage of Development | 8 | 1 |
| Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) Products under Development by Therapy Area | 9 | 1 |
| Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) Products under Development by Indication | 10 | 1 |
| Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) Products under Development by Companies | 13 | 2 |
| Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) Therapeutics Assessment | 15 | 6 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 2 |
| Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) Companies Involved in Therapeutics Development | 21 | 12 |
| Aurigene Discovery Technologies Limited | 21 | 1 |
| BeiGene, Ltd. | 22 | 1 |
| Eli Lilly and Company | 23 | 1 |
| Enumeral Biomedical Holdings, Inc. | 24 | 1 |
| Incyte Corporation | 25 | 1 |
| Interprotein Corporation | 26 | 1 |
| Jounce Therapeutics, Inc. | 27 | 1 |
| Novartis AG | 28 | 1 |
| Sorrento Therapeutics, Inc. | 29 | 1 |
| Sutro Biopharma, Inc. | 30 | 1 |
| Symphogen A/S | 31 | 1 |
| Tesaro, Inc. | 32 | 1 |
| Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) Drug Profiles | 33 | 15 |
| Antibody to Inhibit TIM-3 for Oncology Drug Profile | 33 | 1 |
| AUPM-327 Drug Profile | 34 | 1 |
| Drug to Inhibit PD-1, Gal-9 and TIM-3 for Solid Tumor Drug Profile | 35 | 1 |
| ENUM-005 Drug Profile | 36 | 1 |
| MGB-453 Drug Profile | 37 | 1 |
| Monoclonal Antibody to Inhibit PD-1 and TIM3 for Oncology Drug Profile | 38 | 1 |
| Monoclonal Antibody to Inhibit TIM-3 for Oncology Drug Profile | 39 | 1 |
| Monoclonal Antibody to Inhibit TIM-3 for Oncology Drug Profile | 40 | 1 |
| Monoclonal Antibody to Inhibit TIM3 for Oncology Drug Profile | 41 | 2 |
| Monoclonal Antibody to Inhibit TIM3 for Oncology Drug Profile | 43 | 1 |
| Monoclonal Antibody-3 to Inhibit TIM3 for Oncology Drug Profile | 44 | 1 |
| STI-600 Drug Profile | 45 | 1 |
| Synthetic Peptides to Inhibit TIM-3 for Oncology Drug Profile | 46 | 1 |
| TSR-022 Drug Profile | 47 | 1 |
| Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) Dormant Projects | 48 | 1 |
| Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) Featured News &Press Releases | 49 | 1 |
| Jun 04, 2016: TESARO Provides Update on TSR-022 at ASCO Investor Briefing | 49 | 1 |
| Apr 25, 2016: Tesaro Announces Submission Of Investigational New Drug Application For ANTI-TIM-3 Antibody TSR-022 To The US FDA | 49 | 1 |
| Appendix | 50 | 2 |
| Methodology | 50 | 1 |
| Coverage | 50 | 1 |
| Secondary Research | 50 | 1 |
| Primary Research | 50 | 1 |
| Expert Panel Validation | 50 | 1 |
| Contact Us | 50 | 1 |
| Disclaimer | 51 | 1 |